文献速递甲状腺疾病

伴乳头状核特征的非浸润性滤泡性甲状腺肿瘤(NIFTP)诊断与管理的综合研究

A Comprehensive Study on the Diagnosis and Management of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.
PubMed 文献 · Thyroid · 2023-03-30

该回顾性机构队列纳入2016至2022年319例NIFTP(占甲状腺手术6.6%,其中183例为单纯NIFTP),分析临床、细胞学与分子特征。中位随访35个月(6-76个月;n=120)无复发或转移。作者认为需要共识实践指南指导术后管理,并建议在ATA低危恶性肿瘤指南基础上制定针对交界性/生物学不确定肿瘤的指导。

要点

  • NIFTP占甲状腺手术6.6%,女性:男性为2.7:1,平均年龄52岁,中位肿瘤大小2.1cm。
  • FNA细胞学以AUS/FLUS最常见(49%),分子改变93%为RAS或RAS样。
  • 单纯NIFTP队列中66%经半甲状腺切除术、34%经全甲状腺切除术;中位随访35个月无复发或转移。

核心结论

  • 作者认为,鉴于该大型NIFTP队列(含大量单纯NIFTP、部分随访超过6年且无肿瘤复发),需要共识实践指南以指导充分的术后管理。
  • 作者认为,鉴于美国甲状腺协会(ATA)已提供低危恶性肿瘤管理指南,针对包括NIFTP在内的交界性/生物学不确定肿瘤制定指导是合理的下一步。

研究设计与样本

  • 回顾性机构队列,纳入2016至2022年切除后诊断为NIFTP的319例(占甲状腺手术6.6%,其中183例为单纯NIFTP),收集临床、细胞学与分子数据。

主要发现

  • 患者队列为单灶或多灶甲状腺结节;女性:男性为2.7:1,平均年龄52岁,NIFTP中位大小2.1cm。
  • NIFTP患者中23%(n=73)伴多发结节,12%的NIFTP为多灶性(n=39)。
  • NIFTP的FNA(n=255)结果:无诊断意义5%、良性13%、AUS/FLUS 49%、FN/SFN 17%、可疑恶性12%、恶性4%。
  • 93%(n=114)检出分子改变,为RAS或RAS样;TI-RADS评分4分占50%,3分和5分分别占26%和20%。
  • 单纯NIFTP组(n=183)中66%经半甲状腺切除术(HT)发现、34%经全甲状腺切除术(TT)发现;单因素分析显示TT患者FNA Bethesda类别更高、更常有术前甲状腺功能异常和/或对额外结节行FNA;多因素回归显示,Bethesda V的NIFTP在其他结节接受FNA评估且术前甲状腺功能异常时独立预测TT,Bethesda II的NIFTP与HT显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Since the noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTPs) was introduced in 2016, most retrospective studies have included cases diagnosed as encapsulated follicular variant of papillary thyroid carcinoma. We investigate a cohort diagnosed with NIFTP at resection. Methods: Retrospective institutional cohort of NIFTP from 2016 to 2022, including clinical, cytological, and molecular data for 319 cases (6.6% of thyroid surgeries, 183 cases as NIFTP-only). Results: The patient cohort had unifocal or multifocal thyroid nodules. Female:male ratio was 2.7:1, mean age was 52 years and median NIFTP size was 2.1 cm. NIFTP was associated with multiple nodules in 23% patients (n = 73) and 12% of NIFTP were multifocal (n = 39). Fine needle aspiration (FNA) of NIFTP (n = 255) were designated as nondiagnostic = 5%, benign = 13%, atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) = 49%, follicular neoplasm/suspicious for follicular neoplasm (FN/SFN) = 17%, suspicious for malignancy = 12%, or malignant = 4%. Molecular alterations were identified in 93% (n = 114), RAS or RAS-like. Thyroid Imaging Reporting and Data System (TI-RADS) score 4 was recorded in 50% of NIFTP, followed by scores 3 and 5 (26% and 20%, respectively). We also investigated the factors associated with extent of surgery. In our NIFTP-only group (n = 183), 66% were identified after hemithyroidectomy (HT) and 34% after total thyroidectomy (TT). On univariate analysis, TT patients demonstrated higher Bethesda category by FNA, more often had aberrant preoperative thyroid function, and/or underwent an FNA of additional nodule(s). With multivariable regression, Bethesda V NIFTP, in the presence of other nodules being evaluated by FNA and aberrant preoperative thyroid function, independently predicts TT. Bethesda II NIFTP correlated significantly with HT. Fifty-two patients (28%) with NIFTP-only had at least one postoperative surveillance ultrasound. In the NIFTP-only cohort, no HT patients had completion thyroidectomy or received postoperative radioactive iodine. No recurrence or metastases were recorded with median follow-up of 35 months (6-76 months; n = 120). Conclusions: Given this large cohort of NIFTP, including a large subset of isolated NIFTP-only, some with >6 years of follow-up and no tumor recurrences, consensus practical guidelines are needed for adequate postoperative management. Given the American Thyroid Association (ATA) provides guidelines for management of low-risk malignancies, guidance regarding that for borderline/biologically uncertain tumors, including NIFTP, is a reasonable next step.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Alzumaili BA, Krumeich LN, Collins R, et al. A Comprehensive Study on the Diagnosis and Management of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid. 2023. PMID: 36960710. doi:10.1089/thy.2023.0035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。